Informations générales (source: ClinicalTrials.gov)

NCT02826811 Statut inconnu
Role of Anti-BK Virus Neutralizing Antibodies (BKV) as a Prognostic Marker for the Development of Nephropathy BK
Observational
  • Maladies du rein
University Hospital, Strasbourg, France (Voir sur ClinicalTrials)
juillet 2016
mai 2017
29 juin 2024
BKV nephropathy (BKV) is one of the most frequent complications of kidney transplantation. In the absence of specific anti-BKV treatment, pre-emptive reduction of immunosuppression is the main strategy that has proven effective in reducing the risk of BKVN. However, it exposes a transplant rejection risk estimated between 4 and 14% according to studies. Despite the pre-emptive reduction of immunosuppression, a significant number of patients continue to progress towards BKVN suggesting that pre-emptive strategy is late. It's therefore urgent to develop new prognostic markers to identify earlier and more effectively patients with a higher risk of developing BKVN.
 Voir le détail

Etablissements

Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Service de Virologie - Hôpital Civil - 67091 - Strasbourg - France Samira FAFI-KREMER, PharmD, PhD En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- Patient over 18 years

- Grafted kidney patient between 1 July 2012 and 31 July 2014 at Strasbourg University
Hospital with regular monitoring


- Patient under 18 years